ELPHARMA, the majority shareholder in Bulgaria’s largest pharmaceutical producer Sopharma, subscribed on Monday almost the whole residual package of shares (about 23 per cent after the capital gain). Half an hour after the procedure was opened, brokers Elana Investment announced that a total of 1.558 million shares have already been subscribed, which exceeds the 1.388 million shares of the new stock offered. Elpharma will thus raise its stake from 67 per cent to 85 per cent and the company will receive some BGN five million from the capital gain. Preliminary data show that the sales revenues of the company for the last year amounted to BGN 73.5 million and net profit is expected to reach BGN 14 million. The average salary in the company has been set at BGN 470 after the privatisation and not a single worker has been made redundant.